Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017098461) USE OF AGONISTS OF TYPE-2 DOPAMINERGIC RECEPTORS IN TREATMENT OF CONDITIONS CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/098461 International Application No.: PCT/IB2016/057483
Publication Date: 15.06.2017 International Filing Date: 09.12.2016
Chapter 2 Demand Filed: 26.04.2017
IPC:
A61K 31/48 (2006.01) ,A61P 27/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
48
Ergoline derivatives, e.g. lysergic acid, ergotamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
OFTA SP. Z O. O. [PL/PL]; ul. Skwer Kard. Stefana Wyszyńskiego 5, lok. 6U 01-015 Warszawa, PL
Inventors:
OSĘKA, Maciej; PL
Agent:
DARGIEWICZ, Joanna; PL
Priority Data:
PL41517009.12.2015PL
Title (EN) USE OF AGONISTS OF TYPE-2 DOPAMINERGIC RECEPTORS IN TREATMENT OF CONDITIONS CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS
(FR) UTILISATION D'AGONISTES DES RÉCEPTEURS DOPAMINERGIQUES DE TYPE 2 DANS LE TRAITEMENT DE PATHOLOGIES LIÉES À DES TAUX ÉLEVÉS DU FACTEUR DE CROISSANCE ENDOTHÉLIAL VASCULAIRE
Abstract:
(EN) The present invention relates to a use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.
(FR) La présente invention concerne l'utilisation d'agonistes des récepteurs dopaminergiques de type 2 dans le traitement de maladies oculaires liées à un taux élevé du facteur de croissance endothélial vasculaire (VEGF), en particulier dans le traitement ou la prévention de maladies de la rétine résultant d'une augmentation de la perméabilité des vaisseaux sanguins et de leur angiogenèse à l'aide de cabergoline, un agoniste des récepteurs dopaminergiques D2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: Polish (PL)
Also published as:
CA3007953IL259903CN108472294EP3386509US20180360820